Back to top
more

Exact Sciences (EXAS)

(Real Time Quote from BATS)

$46.82 USD

46.82
1,796,534

-0.94 (-1.97%)

Updated Aug 4, 2025 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top

by Zacks Equity Research

Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.

Zacks Equity Research

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of -43.06% and 3.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.

Zacks Equity Research

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug

by Zacks Equity Research

Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.

Zacks Equity Research

Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bull of the Day: Exact Sciences (EXAS)

by Kevin Cook

EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year

Zacks Equity Research

Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.

Zacks Equity Research

Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

by Zacks Equity Research

Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.

Zacks Equity Research

If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Hologic (HOLX) ThinPrep Genesis Processor Gets FDA Approval

by Zacks Equity Research

Hologic's (HOLX) ThinPrep Genesis processor offers new automation capabilities and workflow enhancements.

Zacks Equity Research

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.

Zacks Equity Research

Exact Sciences (EXAS) Reveals Promising Data on Cologuard

by Zacks Equity Research

Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.

Zacks Equity Research

Strength Seen in Exact Sciences (EXAS): Can Its 9.2% Jump Turn into More Strength?

by Zacks Equity Research

Exact Sciences (EXAS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Zacks Market Edge Highlights: Shopify, PayPal, DraftKings, Exact Sciences and Tesla

by Zacks Equity Research

Zacks Market Edge Highlights: Shopify, PayPal, DraftKings, Exact Sciences and Tesla

Tracey Ryniec headshot

Are You a Glass Half Full or Half Empty Investor?

by Tracey Ryniec

Buying the stock market weakness? Or staying on the sidelines? Your outlook may determine your investing strategy during corrections.

Zacks Equity Research

Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.

Zacks Equity Research

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 82.69% and 4.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Kevin Cook headshot

Bear of the Day: Guardant Health (GH)

by Kevin Cook

Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise

Zacks Equity Research

Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement

by Zacks Equity Research

Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.

Kevin Cook headshot

Software is the New Gold: Storing Value in the Digital-Crypto Age

by Kevin Cook

Time for the final nail in the gilded sarcophagus of the barbarous relic.

Zacks Equity Research

Why Is Exact Sciences (EXAS) Down 8.9% Since Last Earnings Report?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

New Strong Sell Stocks for March 16th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Exact Sciences (EXAS) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.